Cambridge-based biotech company Parabilis Medicines has plans for an initial public offering (IPO) that could raise approximately $450 million by offering 25 million shares priced between $17 and $19 each. Regeneron Pharmaceuticals is also set to support the IPO by purchasing $75 million in shares. This IPO follows a successful year for Parabilis, which secured $305 million in funding and formed a collaboration with Regeneron in 2026, and marks a resurgence in biotech IPOs in Massachusetts, with Parabilis potentially becoming the eighth biotech firm to go public this year. The offering reflects the robust investor interest in biotech and the strength of the Greater Boston life sciences sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://indianewengland.com/under-ceo-mathai-mammen-cambridge-biotech-parabilis-medicines-pursues-450-million-ipo/
